A new descriptor via bio-mimetic chromatography and modeling for the blood brain barrier (Part II).
Within the context of drug design methodology for the central nervous system (CNS), a predictive model which can shorten the process of finding new candidate drugs was developed. Therefore, the retention time of 51 molecules which are clinically established to enter the blood brain barrier (BBB), were recorded on two HPLC columns. For this purpose, a lipophilic butyl (C4) stationary phase was used to simulate the behavior of a drug regarding BBB permeability and a zwitterionic-HILIC to simulate blood. The results were plotted as Y variables on two Partial Least Squares (PLS) models, while 25 specific physicochemical properties (significant for lipid bilayers BBB permeation or blood) were used as X descriptors. Both models can be utilized to predict the drugability of a new molecule avoiding needless animal experiments, as well as time and material consuming syntheses. The developed models were validated (R2 ≥ 0.90, Q2 ≥ 0.83), and based on the results specific variables were proved to be significant for the studied phenomenon. Additionally, a new factor symbolized as MT was introduced. MT incorporated the experimental results and it was calculated by the fraction of the sum of the retention time of the drug on the two columns (tr(butyl) + tr(HILIC)) divided by the molecular volume (Vm) of each analyte. This new descriptor was used as an equivalent to the logarithm of BBB permeability (logBB) and may indicate the ability of a new molecule to act as a candidate drug able to enter the BBB. Comprehending the extend of contribution of several molecular attributes to the in vivo distribution of a drug may enlighten the knowledge on pharmacokinetics and clinical variation, and enable scientists to design more efficient drug molecules.